Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.

British journal of cancer - 13 Mar 2012

Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S, Evans D G, Ross G, Eccles D, Tutt A, Rahman N

Abstract excerpt

BACKGROUND: Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer. METHODS: We undertook BRCA1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Testing

Share to Incidence

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 22333603
DOI: 10.1038/bjc.2012.31
PMCID: PMC3304410

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.PMID 22333603Read ↗

Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.Semantic proximity Read ↗

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historySemantic proximity Read ↗

Expanding the criteria for BRCA mutation testing in breast cancer survivors.Semantic proximity Read ↗

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.Semantic proximity Read ↗

Genetic testing in a cohort of young patients with HER2-amplified breast cancer.Semantic proximity Read ↗

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.Semantic proximity Read ↗

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.Semantic proximity Read ↗

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.Semantic proximity Read ↗

Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Semantic proximity Read ↗

BRCA1 mutations in southern England.Semantic proximity Read ↗

Characteristics of Triple-Negative Breast Cancer in Patients With a <i>BRCA1</i> Mutation: Results From a Population-Based Study of Young WomenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.